Be part of the knowledge.™

Neurology and Neurosurgery

90

LikeLikedUnlike

1-15 of 116

When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
CME/CE Virtual Event
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
October 07, 2026
06:00 PM - 07:00 PM CEST
1.00 credits
An Exclusive Peer Dinner with Gil I. Wolfe MD, FAAN, Discussing Advancing Treat-to-Target Care in Generalized Myasthenia Gravis
CME/CE In-Person Event
An Exclusive Peer Dinner with Gil I. Wolfe MD, FAAN, Discussing Advancing Treat-to-Target Care in Generalized Myasthenia Gravis
October 10, 2026
New York, New York
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 22, 2026
Austin, Texas
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 23, 2026
Houston, Texas
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
October 24, 2026
Atlanta, Georgia
1.50 credits
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
November 05, 2026
Phoenix, Arizona
1.50 credits
advertisement
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
CME/CE In-Person Event
Advancing Treat-to-Target Care in Generalized Myasthenia Gravis: Earlier Diagnosis, Standardized Assessment, and Precision Use of FcRn-Directed Therapy
November 07, 2026
Miami, Florida
1.50 credits
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
CME/CE Broadcast Replay
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
- Dani Cabral, MD
- David Weisman, MD
1.00 credits
Stroke-Like Symptoms During Treatment: Safety First
MinuteCE®
Stroke-Like Symptoms During Treatment: Safety First
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Antithrombotics and Amyloid Therapy: Balancing Risk
MinuteCE®
Antithrombotics and Amyloid Therapy: Balancing Risk
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Who Is Ready for Amyloid-Targeting Therapy?
MinuteCE®
Who Is Ready for Amyloid-Targeting Therapy?
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
Talking Through Benefits, Risks, and Patient Priorities
MinuteCE®
Talking Through Benefits, Risks, and Patient Priorities
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
advertisement
Borderline Biomarkers: When a Blood Test Is Not Enough
MinuteCE®
Borderline Biomarkers: When a Blood Test Is Not Enough
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits
MinuteCE®
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic Alzheimer’s Disease
- Dani Cabral, MD
- David Weisman, MD
0.50 credits 6 episodes
Recognizing ARIA Before Symptoms Appear
MinuteCE®
Recognizing ARIA Before Symptoms Appear
- Dani Cabral, MD
- David Weisman, MD
0.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended